FibroGen, Inc.
NASDAQ:FGEN
0.32 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | FibroGen, Inc. |
Symbool | FGEN |
Munteenheid | USD |
Prijs | 0.319 |
Beurswaarde | 32,017,879 |
Dividendpercentage | 0% |
52-weken bereik | 0.29 - 2.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thane Wettig |
Website | https://www.fibrogen.com |
An error occurred while fetching data.
Over FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)